DIAGNOS Announces Contract Renewal and Expansion in the UAE

Diagnos Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in
healthcare technical services including, screening, software and algorithm
development, data analysis, and image processing, announced today the signing of
a renewal of a client agreement originally announced on January 15th 2013, and
the expansion of CARA deployment in the United Arab Emirates.


"Over the course of the past year we have been working very closely with our UAE
clients as well as with local healthcare providers and facilities. During the
period between January 1st and October 31st 2013, we have had multiple screening
systems deployed within 35 affiliated healthcare facilities across the United
Arab Emirates. We estimate that approximately 650 patients were referred to
retina specialists thus far in 2013 and given the opportunity to save their
vision. Our client in the United Arab Emirates view our CARA screening platform
as an effective and efficient tool within the context of their strategic
initiatives, and have consequently decided to scale-up activities for 2014. We
are very excited by increases in demand for screening programs and we are
pleased to announce that we are doubling the current CARA deployment to meet
market demand. We are pleased to announce that the value of our project with our
lead Pharma client has been doubled to $220,000 for 2014, with screenings
starting this November to coincide with World Diabetes Day on November 14th,"
said Peter Nowacki, Diagnos' Vice-President.


About Diabetes

Diabetes kills one person every six seconds and afflicts 382 million people
worldwide, according to the International Diabetes Federation (IDF), which has
been canvassing the help of people ranging from celebrity chef Jamie Oliver to
Bob Marley's nephew to raise awareness about the problem. The number of diabetes
cases has climbed 4.4 percent over the past two years and is more than 5 percent
of the world's population, according to new figures the IDF released last week.
The number of people affected by the disease is expected to climb 55 percent to
592 million by 2035 as factors including poor diet, a more sedentary lifestyle,
and increases in obesity and life expectancy fuel an epidemic. There were only
285 million sufferers worldwide in 2009. "We haven't seen any kind of
stabilizing, any kind of reversal," Leonor Guariguata, an epidemiologist and
project coordinator for IDF's Diabetes Atlas. "Diabetes continues to be a very
big problem and is increasing even beyond previous projections." The disease,
caused by a lack of insulin the body needs to convert blood sugar into energy,
is becoming a financial burden on governments, and led to $548 billion in global
health-care spending this year, the federation said. To counter the surge, it
recommends policy makers across many sectors should devise concerted action.
More information on diabetes is available on the IDF web site www.idf.org. 


About DIAGNOS

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a
mission to commercialize technologies combining contextual imaging and
traditional data mining thereby improving decision making processes. DIAGNOS
offers products, services, and solutions to clients in a variety of fields
including healthcare and natural resources. 


Neither the TSX Venture Exchange nor its Regulation Service Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


For further information on DIAGNOS, please visit our website at www.diagnos.com
or the SEDAR website at www.sedar.com.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Andre Larente
President
DIAGNOS Inc.
(450) 678-8882 ext 224


Louis Morin
Bid Capital Markets
(514) 845-1101

Diagnos (TSXV:ADK)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024